These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 21802969)

  • 1. An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.
    El-Gharbawy AH; Mackey J; DeArmey S; Westby G; Grinnell SG; Malovrh P; Conway R; Kishnani PS
    Mol Genet Metab; 2011; 104(1-2):118-22. PubMed ID: 21802969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa.
    Lipinski SE; Lipinski MJ; Burnette A; Platts-Mills TA; Wilson WG
    Mol Genet Metab; 2009 Nov; 98(3):319-21. PubMed ID: 19640753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions.
    Ditters IAM; van Kooten HA; van der Beek NAME; Hardon JF; Ismailova G; Brusse E; Kruijshaar ME; van der Ploeg AT; van den Hout JMP; Huidekoper HH
    BioDrugs; 2023 Sep; 37(5):685-698. PubMed ID: 37326923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First successful concomitant therapy of immune tolerance induction therapy and desensitization in a CRIM-negative infantile Pompe patient.
    Emecen Sanli M; Ertoy Karagol HI; Kilic A; Aktasoglu E; Inci A; Okur I; Ezgu F; Tumer L
    J Pediatr Endocrinol Metab; 2022 Feb; 35(2):273-277. PubMed ID: 34561975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa.
    Gragnaniello V; Fecarotta S; Pecoraro A; Tarallo A; Catzola A; Spadaro G; Parenti G; Della Casa R
    Neurol Sci; 2019 Jul; 40(7):1453-1455. PubMed ID: 30778879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.
    Nicolino M; Byrne B; Wraith JE; Leslie N; Mandel H; Freyer DR; Arnold GL; Pivnick EK; Ottinger CJ; Robinson PH; Loo JC; Smitka M; Jardine P; Tatò L; Chabrol B; McCandless S; Kimura S; Mehta L; Bali D; Skrinar A; Morgan C; Rangachari L; Corzo D; Kishnani PS
    Genet Med; 2009 Mar; 11(3):210-9. PubMed ID: 19287243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study.
    van Gelder CM; Poelman E; Plug I; Hoogeveen-Westerveld M; van der Beek NAME; Reuser AJJ; van der Ploeg AT
    J Inherit Metab Dis; 2016 May; 39(3):383-390. PubMed ID: 26768149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
    Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients.
    Poelman E; van den Dorpel JJA; Hoogeveen-Westerveld M; van den Hout JMP; van der Giessen LJ; van der Beek NAME; Pijnappel WWMP; van der Ploeg AT
    J Inherit Metab Dis; 2020 Nov; 43(6):1243-1253. PubMed ID: 32506446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
    Strothotte S; Strigl-Pill N; Grunert B; Kornblum C; Eger K; Wessig C; Deschauer M; Breunig F; Glocker FX; Vielhaber S; Brejova A; Hilz M; Reiners K; Müller-Felber W; Mengel E; Spranger M; Schoser B
    J Neurol; 2010 Jan; 257(1):91-7. PubMed ID: 19649685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
    Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
    Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
    Papadopoulos C; Orlikowski D; Prigent H; Lacour A; Tard C; Furby A; Praline J; Solé G; Hogrel JY; De Antonio M; Semplicini C; Deibener-Kaminsky J; Kaminsky P; Eymard B; Taouagh N; Perniconi B; Hamroun D; Laforêt P;
    Mol Genet Metab; 2017 Sep; 122(1-2):80-85. PubMed ID: 28648663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical immunologic response in a patient with CRIM-negative Pompe disease.
    Abbott MA; Prater SN; Banugaria SG; Richards SM; Young SP; Rosenberg AS; Kishnani PS
    Mol Genet Metab; 2011 Dec; 104(4):583-6. PubMed ID: 21889385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
    Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
    Front Immunol; 2020; 11():1727. PubMed ID: 32849613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
    Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
    Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.